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Background
Glioblastoma, despite the use of radiation and che-
motherapy, remains vastly lethal. Cancer immunotherapy
has entered the era of maturity with new compounds like
anti-PD-1 FDA approved to treat advanced tumors.
However, the use of immunotherapy in the setting of
chemotherapy presents challenges, as chemotherapy
causes lymphodepletion and potentially antagonizes
immunotherapy. In this work, we studied ways to opti-
mize the delivery of chemotherapy in the setting of
immunotherapy.
Methods
Using the GL-261 mouse glioblastoma model, we car-
ried out a series of survival, immunophenotypic and
mechanistic experiments to identify the optimal timing
and delivery method of chemotherapy (BCNU, temozo-
lomide) in relation to immunotherapy (anti-PD-1).
Results
Local chemotherapy (LC) in the form of chemotherapy
eluted polymer combined with anti-PD-1 monoclonal
antibody led to superior survival and tumor eradication
compared to monotherapies and the combination of
anti-PD-1 with systemic chemotherapy. The use of sys-
temic chemotherapy abrogated the survival benefit anti-
PD-1 produced as a monotherapy in a dose dependent
manner. Furthermore, systemic chemotherapy caused
lymphopenia and decreased T cell effector function in a
dose dependent fashion, while the combination of LC
and anti-PD-1 resulted in the highest immune activa-
tion. LC increased the infiltration of dendritic cells
intratumorally. Utilizing the antigen specific ova system
we showed that LC allowed for expansion of antigen
specific T cells while systemic chemotherapy thwarted
the homing and expansion of these cells. We additionally
found that systemic chemotherapy abrogated the creation
of long-term memory that anti-PD-1 alone created. Mice
treated with anti-PD-1 and systemic chemotherapy and
rechallenged with GL-261 tumors failed to reject the
tumor due to the persistent lymphodepletion caused by
systemic chemotherapy as well as functional impairment
of T memory cells. However, LC in combination with
anti-PD1 preserved a long-term memory response. We
further studied the long-term effects of SC in immu-
notherapy; mice treated with SC for 2 weeks were given
an extended chemotherapy break (2 months) to allow the
immune system to rest and were subsequently treated
with anti-PD-1. Surprisingly, these mice failed to show
the same survival benefit anti-PD-1 only treated mice
exhibited.
Conclusions
LC in combination with anti-PD-1 creates a robust antitu-
mor immune response, increases antigen presentation and
expands tumor specific T cells resulting in the cure of well
established tumors in the majority of mice, while at the
same time preserves a long-term memory antitumor
response.
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